Also, SUL (3 and 10 mg/kg) treatment, a stable OEA-modeled compound, in addition to PPAR-α antagonist, GW6471 (1 mg/kg), improves the brain damage and accompanying motor and cognitive impairments caused by hypoxia-ischemia in mice, most likely through regulating alterations in neuroinflammation/immune system mediators [39]. This evidence concerns the gene PPARA and Cognitive impairment.